Children's National Medical Center
Acute Leukemia Advocates Network; Leukaemia Care
Dominican University of California
Brandon Regional Hospital
Jak2/Stat5 Pathway Mutation Frequencies In South African Bcr/Abl Negative Mpn Patients,
2023
Division of Haematology, Department of Pathology, Faculty of Health Science, University of Cape Town
Jak2/Stat5 Pathway Mutation Frequencies In South African Bcr/Abl Negative Mpn Patients, Shires K, Rust A, Harryparsad R, Coburn J, Gopie R
Hematology/Oncology and Stem Cell Therapy
Background: Mutations in JAK2/STAT5 proliferation pathway genes are key in the diagnosis of myeloproliferative neoplasms (MPNBCR/ABLneg), with JAK2V617F being found in 50-97% of MPNBCR/ABLneg subtypes. Low JAK2V617F positivity at our facility suggested that our South African MPNBCR/ABLneg population may have a different mutational landscape. Objectives: We aimed to determine the JAK2/STAT5 mutation frequencies associated with our local MPNBCR/ABLneg population, thus determining the relevance of these molecular tests in this group. We also investigated the haematopathological relevance of each test request, to assess testing practises. Method: This study involved the retrospective audit of 886 patients for whom JAK2V617F mutation testing had …
Acquired Amegakaryocytic Thrombocytopenic Purpura: A Review Of Therapeutic Options,
2023
Department of Internal Medicine, Rochester General Hospital, Rochester, New York
Acquired Amegakaryocytic Thrombocytopenic Purpura: A Review Of Therapeutic Options, Syed Ather Hussain, Aneeqa Zafar, Hafsa Faisal, Mohammad Ammad Ud Din
Hematology/Oncology and Stem Cell Therapy
Acquired amegakaryocytic thrombocytopenic purpura (AATP) is a rare bone marrow disorder characterized by either a marked decrease or a complete absence of megakaryocytes with preservation of all other cell lines. More than 60 cases of AATP have been reported in literature thus far. Due to the rarity of this disease, no standard treatment guidelines have been established and therapy is based on a handful of case studies and expert opinion. Herein, we provide a comprehensive review on currently utilized therapeutic options for AATP.
Prevalence Of Iron Deficiency In Patients With Inherited Bleeding Disorders,
2023
Children's Mercy Hospital
Prevalence Of Iron Deficiency In Patients With Inherited Bleeding Disorders, Thomas Cochran, Brian Lee, Shannon Carpenter
Posters
Background: Synthesis of hemoglobin is one of several important roles iron plays in the human body. Approximately 50% of all anemia cases may be caused by iron deficiency which is frequently caused by chronic blood loss. Patients with bleeding disorders have greater propensity for blood loss and therefore may have a higher prevalence of iron deficiency when compared to the general population. However, few studies have assessed the prevalence of iron deficiency in children with inherited bleeding disorders. Objectives: This study aims to identify the prevalence of iron deficiency in children with an inherited bleeding disorder. Methods: A retrospective analysis …
The Immunomodulating Effects Of Morphine Dependence And Withdrawal In A Rat Model,
2023
Roseman University of Health Sciences
The Immunomodulating Effects Of Morphine Dependence And Withdrawal In A Rat Model, Mark Stoll
Annual Research Symposium
Would you like to know what happens to the immune system during opioid drug withdrawal?
Frequency Of Von Willebrand Disease And Its Types: Data From A Tertiary Care Hospital Of Karachi, Pakistan,
2023
Aga Khan University
Frequency Of Von Willebrand Disease And Its Types: Data From A Tertiary Care Hospital Of Karachi, Pakistan, Jyoti Mohan Lal, Anila Rashid, Natasha Ali
Department of Pathology and Laboratory Medicine
Introduction: von Willebrand disease is the most common inherited bleeding disorder. It is classified into 3 main types, type I and III are quantitative defects whereas type II is qualitative defect which is further sub-classified in to II-A, II-B, II-M, II-N. The aim of the present study is to see frequency and types of von Willebrand disease in a tertiary care hospital of Karachi, Pakistan.
Materials and methods: This retrospective cross-sectional study was conducted in the section of Hematology and Transfusion Medicine, Department of Pathology and Laboratory Medicine, the Aga Khan University hospital, Karachi, from May 2020 to April 2021 …
Understanding Quality Of Life In Patients With Acute Leukemia, A Global Survey,
2023
Acute Leukemia Advocates Network; Leukaemia Care
Understanding Quality Of Life In Patients With Acute Leukemia, A Global Survey, Zack Pemberton-Whiteley, Samantha Nier, Jan Geissler, Sophie Wintrich, Bregje Verhoeven, Rita O. Christensen, Sam Salek, Esther Natalie Oliva, Tatyana Ionova, Jennie Bradley
Journal of Patient-Centered Research and Reviews
Purpose: The Acute Leukemia Advocates Network (ALAN) sought to determine which factors are most associated with poor quality of life (QoL) in patients with acute leukemia and to determine key issues and unmet needs through administration of an online survey distributed worldwide via partner patient organizations.
Methods: ALAN developed a questionnaire informed by literature review and based extensively on the hematological malignancy-specific patient-reported outcomes (HM-PRO) measure to assess the impact of acute leukemia on QoL and its relationships with patients’ demographics, disease state, disease impact, and support from health care professionals. Univariate and multivariable statistical analysis was used to investigate …
Predicting If Lung Cancer Will Relapse—The Role Of Neutrophil/Lymphocyte Ratio,
2023
Department of Medicine, Sinai Hospital of Baltimore, Baltimore, MD 21215, USA
Predicting If Lung Cancer Will Relapse—The Role Of Neutrophil/Lymphocyte Ratio, Abigail Chan, Søren Bentzen, Amit Rout, Kenneth Miller
Hematology/Oncology and Stem Cell Therapy
Objective/Background: Baseline neutrophil/lymphocyte ratio (NLR), a surrogate marker for systemic inflammation and immunosuppression, is a well-studied prognostic marker in nonsmall cell lung cancer (NSCLC). This study tests if interim NLR is prognostic in NSCLC patients in remission. Methods: This single-center, retrospective cohort study analyzed 131 NSCLC patients treated from 2010 to 2015 who achieved complete remission. NLR was calculated at baseline and from the first available blood sample during remission. Kaplan–Meier estimates of overall survival (OS) and time to recurrence were compared using the log-rank test for trend. Multivariable analysis was conducted using the Cox proportional hazards model. Results: Of …
Impact Of Pre-Transplant Induction Therapy On Outcomes Of Patients Who Undergo Autologous Stem Cell Transplantation For Mantle Cell Lymphoma In First Complete Remission,
2023
Department of Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, MI, USA
Impact Of Pre-Transplant Induction Therapy On Outcomes Of Patients Who Undergo Autologous Stem Cell Transplantation For Mantle Cell Lymphoma In First Complete Remission, Omar Albanyan, Samer Alkassis, Seongho Kim, Andrew Kin, Asif Alavi, Lois Ayash, Voravit Ratanatharathorn, Dipenkumar Modi, Joseph P. Uberti, Abhinav Deol
Hematology/Oncology and Stem Cell Therapy
Mantle cell lymphoma is a rare subtype of non-Hodgkin’s lymphoma with poor prognosis and continue to be challenging to treat. The choice of first line induction regimen remains a topic of debate due paucity of clinical trials. We retrospectively evaluated 66 patients diagnosed with mantle cell lymphoma who achieved first complete response after induction chemotherapy followed by autologous stem cell transplant. Treatment groups were divided into lowintensity versus high-intensity regimens. Our data showed the intensity of induction regimen does not impact posttransplant outcomes of mantle cell lymphoma who underwent autologous stem cell transplant in first complete response.
Promising Effect Of Pdl1 Inhibitors In The Front-Line Management Of Primary Aggressive Central Nervous System Lymphoma: A Case Report,
2023
Department of Hematology, Kuwait Cancer Control Center, Kuwait
Promising Effect Of Pdl1 Inhibitors In The Front-Line Management Of Primary Aggressive Central Nervous System Lymphoma: A Case Report, Rasha El-Tawab, Abdulaziz Hamada, Rehab Elhagracy, Karen Pinto, Salem Alshemmari
Hematology/Oncology and Stem Cell Therapy
Primary central nervous system lymphoma (PCNSL) is a rare lymphoma that involves the central nervous system. The standard treatment involves chemotherapy with high-dose methotrexate. To the best of our knowledge, this is the first reported case of employing checkpoint inhibitor, nivolumab, alone to treat a patient with PCNSL who could not tolerate the induction therapy. In aggressive cases of PCNSL where chemotherapy may become futile, stand-alone checkpoint inhibitors should be considered as the front-line treatment protocol.
Predictors And Management Of Relapse To Axicabtagene Ciloleucel In Patients With Aggressive B-Cell Lymphoma,
2023
Department of Internal Medicine, Division Hematology-Oncology, Mayo Clinic, Phoenix, AZ, USA
Predictors And Management Of Relapse To Axicabtagene Ciloleucel In Patients With Aggressive B-Cell Lymphoma, Jose Vicente Forero-Forero, Paula A. Lengerke-Diaz, Eider Moreno-Cortes, Megan Melody, Zaid Abdel Rahman, Allison C. Rosenthal, Mohamed A. Kharfan-Dabaja, Januario E. Castro
Hematology/Oncology and Stem Cell Therapy
Objective/background: Despite the success of chimeric antigen receptor (CAR) T-cell therapy in patients with aggressive non-Hodgkin lymphoma (aNHL), some patients still fail treatment, and their prognosis is dismal. Methods: We performed a retrospective study of aNHL patients treated with axicabtagene ciloleucel (axi-cel) at two Mayo Clinic centers between 2018 and 2020. We evaluated predictive factors, toxicities, and responses to salvage regimens after CAR T-cell therapy. Results: Thirty-four patients received axi-cel with a median length of hospitalization of 14 days. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome of any grade occurred in 91% and 41% of patients, respectively. …
Immune Checkpoint Inhibitor-Induced Pneumonitis: Incidence, Clinical Characteristics, And Outcomes,
2023
Division of Pulmonary, Critical Care and Sleep Medicine, Wayne State University School of Medicine, Detroit, MI, USA
Immune Checkpoint Inhibitor-Induced Pneumonitis: Incidence, Clinical Characteristics, And Outcomes, Harsha Banavasi, Seongho Kim, Samer Alkassis, Asil Daoud, Amir Laktineh, Misako Nagasaka, Ammar Sukari, Ayman O. Soubani
Hematology/Oncology and Stem Cell Therapy
Background: Immune checkpoint inhibitors (ICIs) are the newest class of anticancer drugs. Pneumonitis is increasingly being recognized as a potential complication of these agents. Methods: We conducted a retrospective study of patients who received ICIs at a comprehensive cancer center. We collected data on demographics, type of malignancy, type of ICI agent, incidence of pneumonitis up to 6 weeks after receiving ICI agent, clinical characteristics, and risk factors for overall survival in patients who develop pneumonitis. Results: A total of 654 patients received ICIs during the study period. The most common type of cancer for which ICI was given was …
Changes In Heme Levels During Acute Vaso-Occlusive Crisis In Sickle Cell Anemia,
2023
Hematology and Hemotherapy Foundation from Amazonas State (HEMOAM), Manaus, AM, Brazil
Changes In Heme Levels During Acute Vaso-Occlusive Crisis In Sickle Cell Anemia, Evilazio Cunha Cardoso, Pedro Vieira Silva-Neto, Bidossessi Wilfried Hounkpe, Francine Chenou, Cintia Cristina Mateus Xerez Albuquerque, Nadja Pinto Garcia, Alexander Leonardo Silva-Junior, Adriana Malheiro, Purim Cesar, Franciele De Lima, Erich V. De Paula, Nelson Abrahim Fraiji
Hematology/Oncology and Stem Cell Therapy
Objective/Background: Sickle cell anemia (SCA) is associated with increased levels of extracellular heme, which is a key mediator of inflammation in this condition. Despite abundant evidence supporting this concept in cell and animal models, few studies addressed the association between heme levels and the development and severity of acute vaso-occlusive crises (VOC) in humans. Methods: A cross-sectional study was conducted in patients with acute VOC. Total extracellular heme levels were measured in both plasma and serum at admission and after convalescence, and correlated with other clinical and laboratory markers of SCA severity. Results: A total of 28 episodes of VOC …
Diagnosis And Treatment Of Subcutaneous Panniculitis-Like T-Cell Lymphoma: A Systematic Literature Review,
2023
King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
Diagnosis And Treatment Of Subcutaneous Panniculitis-Like T-Cell Lymphoma: A Systematic Literature Review, Dunya Yunus Alsomali, Nasir Bakshi, Mohamed Kharfan-Dabaja, Riad El Fakih, Mahmoud Aljurf
Hematology/Oncology and Stem Cell Therapy
Objectives: The aim of this systematic review is to investigate different diagnostic methods and the available treatment options for subcutaneous panniculitis-like T-cell lymphoma (SPTCL). Methods: We searched PubMed, Web of Science, SCOPUS, EBSCO, and CINAHL Plus for published case reports of SPTCL. From each record, we extracted data of the diagnostic methods, immunohistochemical profile, clinical characteristics, and the treatment approaches provided. Data were summarized and narratively synthesized to highlight the various diagnostic methods and treatment options of SPTCL. Results: Our literature search yielded 1293 unique citations. Following screening, nine articles reporting a total of 15 cases were included in this …
Cross Fire: Daratumumab-Based Therapies Are Standard Of Care In Newly Diagnosed Multiple Myeloma,
2023
Multiple Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Cross Fire: Daratumumab-Based Therapies Are Standard Of Care In Newly Diagnosed Multiple Myeloma, Neha Korde, Saad Z. Usmani
Hematology/Oncology and Stem Cell Therapy
There is no abstract.
Current Status And Future Perspectives On The Internet Of Things In Oncology,
2023
Department of Medicine, Houston Methodist Hospital, Houston, TX, USA
Current Status And Future Perspectives On The Internet Of Things In Oncology, Ibrahim N. Muhsen, Omar W. Rasheed, Eiad A. Habib, Rakan K. Alsaad, Mohannad K. Maghrabi, Md A. Rahman, Douglas Sicker, William A. Wood, Muhammad S. Beg, Anthony D. Sung, Shahrukh K. Hashmi
Hematology/Oncology and Stem Cell Therapy
The Internet of Things (IoT) has penetrated many aspects of everyday human life. The use of IoT in healthcare has been expanding over the past few years. In this review, we highlighted the current applications of IoT in the medical literature, along with the challenges and opportunities. IoT use mainly involves sensors and wearables, with potential applications in improving the quality of life, personal health monitoring, and diagnosis of diseases. Our literature review highlights that the current main application studied in the literature is physical activity tracking. In addition, we discuss the current technologies that would help IoT-enabled devices achieve …
Efficacy And Safety Of Recombinant Thrombomodulin For The Prophylaxis Of Veno-Occlusive Complication In Allogeneiccit Hematopoietic Stem Cell Transplantation: A Systematic Review And Meta-Analysis,
2023
North Alabama Medical Center, Florence, AL, USA
Efficacy And Safety Of Recombinant Thrombomodulin For The Prophylaxis Of Veno-Occlusive Complication In Allogeneiccit Hematopoietic Stem Cell Transplantation: A Systematic Review And Meta-Analysis, Richi Kashyap, Faiz Anwer, Muhammad Areeb Iqbal, Farhan Khalid, Anam Khan, Muhammad Ashar Ali, Muhammad Yasir Anwar, Anamika Chaudhary, Ali Jaan
Hematology/Oncology and Stem Cell Therapy
Background: Hepatic veno-occlusive disease (VOD), also termed as sinusoidal obstruction syndrome (SOS), is a lethal complication after hematopoietic stem cell transplantation (HSCT). Various factors put patients undergoing allogeneic HSCT at an increased risk for VOD. Thrombomodulin (TM) is an important factor which has a wide range of effects, including anticoagulant, anti-inflammatory, angiogenic, and protective effect, on endothelial cells. It plays a role in preventing excessive coagulation and thrombosis by binding with thrombin and inhibiting the coagulation cascade. There are a limited number of options for the prevention of this fatal complication. Recombinant thrombomodulin (rTM), an endothelial anticoagulant co-factor,
as prophylactic …
Strange Bedfellows: Npm1 Mutations In Acute Promyelocytic Leukemia,
2023
Cancer Molecular Diagnostics, St. James’s Hospital, Dublin, Ireland
Strange Bedfellows: Npm1 Mutations In Acute Promyelocytic Leukemia, Stephen E. Langabeer
Hematology/Oncology and Stem Cell Therapy
No Abstract for this article type
Outcome Of Myeloma Patients With Covid-19 On Active Lenalidomide-Based Therapy: Does Lenalidomide Protect From Severe Covid-19?,
2023
Department of Adult Hematology and Bone Marrow Transplantation, King Fahad Medical City, Riyadh, Saudi Arabia
Outcome Of Myeloma Patients With Covid-19 On Active Lenalidomide-Based Therapy: Does Lenalidomide Protect From Severe Covid-19?, Imran K. Tailor, Nawal F. Alshehry, Syed Z. Zaidi, Mohammed A. Marei, Ibraheem H. Motabi, Mansour Alfayez, Syed Y. Altaf
Hematology/Oncology and Stem Cell Therapy
No abstract for this article type.
Use Of Checkpoint Inhibitors In Gray Zone Lymphoma,
2023
Universidade Federal do Ceara´, Fortaleza, Ceara´, Brazil
Use Of Checkpoint Inhibitors In Gray Zone Lymphoma, Yensy Mariana Zelaya Rosales, Juliene Lima Mesquita, Yhasmine Delles Oliveira Garcia, Fernando Ricardo Fernandes Paz, Naiana Castelo Branco Campos, Joa˜O Paulo De Vasconcelos Leita˜O, Francisco Da´Rio Rocha Filho, Ricardo Vale Albino Oliveira Filho, Rome´Lia Pinheiro Gonc¸Alves Lemes, Fernando Barroso Duarte
Hematology/Oncology and Stem Cell Therapy
Checkpoint inhibitors, cancer immunotherapies, are the new forms of treatment for gray zone lymphoma, a rare subtype that combines the characteristics of both Hodgkin and non-Hodgkin disease forms. Programmed cell death protein 1/programmed cell death ligand 1 (PD-L1/PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) modulate the immune system function. Immunological checkpoints can be stimulatory or inhibitory, and tumors can use these checkpoints to protect against immune system attacks. This is a case report of a difficult diagnosis and describes the most current treatment using checkpoint inhibitors, through the review of the clinical record of a patient diagnosed with gray area …
High Expression Of Long Noncoding Rna Norad Is Associated With Poor Clinical Outcomes In Non-M3 Acute Myeloid Leukemia Patients,
2023
Department of Hematology, School of Medicine, Tarbiat Modares University (TMU), Tehran, Iran.
High Expression Of Long Noncoding Rna Norad Is Associated With Poor Clinical Outcomes In Non-M3 Acute Myeloid Leukemia Patients, Mohammad Masoud Eslami, Mina Soufizomorrod, Mohammad Ahmadvand
Hematology/Oncology and Stem Cell Therapy
Objective/Background: Dysregulation of long noncoding RNA NORAD has been identified in human solid tumors. However, the expression profile of NORAD and its clinical implications in acute myeloid leukemia (AML) is unclear. The current study aimed to explore the NORAD expression status and its clinical significance in non-M3 AML patients. Methods: NORAD expression was evaluated in 60 de novo non-M3 AML patients and 49 healthy individuals using quantitative reverse transcription–polymerase chain reaction method. The correlation between NORAD transcription levels and clinicopathologic characteristics was statistically studied. Results: Compared with the healthy controls, NORAD was consistently higher in non-M3 AML patients (p = …
